Navigation Links
Immtech to be Listed on OTC Market
Date:5/21/2009

NEW YORK, May 21 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (OTC: IMMP) announced today that the Company expects to begin trading its common stock on the Pink OTC Markets quotation system on or about Friday, May 22, 2009 under the ticker symbol "IMMP".

As announced previously, on March 27, 2009 the Company received notice from the NYSE AMEX (the "Exchange") of its intention to initiate proceedings to delist the Company's common stock. The Corporate Compliance Department of NYSE Regulation, Inc., on behalf of the Exchange, determined that the Company was not in compliance with certain of the Exchange's continued listing standards, as set forth in the Exchange's Company Guide, including Section 1003(a)(ii), Section 1003(a)(iii) and Section 1003(a)(iv). The Listing Qualifications Panel of the Exchange's Committee on Securities affirmed the Exchange's earlier determination to delist the common stock of the Company, and the Exchange has notified the Company that trading in its common stock will cease on the Exchange effective at close of trading on Thursday, May 21, 2009.

Eric L. Sorkin, Chairman and Chief Executive Officer stated, "Immtech believes it has a strong development plan for its valuable platform of proprietary compounds and extensive knowledge and networks in China. We plan to vigorously utilize our competitive advantages and aim to fully enhance shareholder value. We will continue to seek high growth opportunities for the Company."

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. and subsidiaries (a development stage enterprise) is focused on global development in the healthcare sector and opportunities in China. Immtech aims to apply its established expertise and other assets in both new drug development and enhanced healthcare-related services, including research and content distribution services, for developed and developing countries. For additional information, please visit the Company's website at http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2008 filed on June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) conditions in the credit markets and the general economy; (ii) Immtech's ability to obtain additional funds; (iii) Immtech's ability to manage its remaining resources; (iv) Immtech's ability to continue as a going concern; (v) Immtech's ability to retain key personnel; (vi) the ability of Immtech's scientists and collaborators to discover new compounds; (vii) the availability of additional research grants; (viii) Immtech's ability to obtain regulatory approval of its drug candidates; (ix) the success of Immtech's clinical trials; (x) dependence upon and contractual relationship with partners; (xi) Immtech's ability to protect its intellectual property; and (xii) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Completes Malaria Prevention Trial
2. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
3. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
4. Immtech Investor Conference Call Scheduled for February 22, 2008
5. Immtech Announces Update on Business Operations
6. Immtech Announces Results From Hepatitis C Discovery Program
7. Immtech Reports Fiscal Year End 2008 Results
8. Immtech Investor Conference Call Scheduled for June 25, 2008
9. Immtech Reports Fiscal Second Quarter 2009 Results
10. Immtech Receives Listing Notice From NYSE Alternext US
11. Immtech Announces Sale of Property Subsidiary in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... 25, 2017 , ... FCPX LUT Vintage Volume 2 for Final Cut Pro ... Vintage Volume 2 contains 60 different color-grade presets, giving editors multiple options for adding ... to single out subjects, plus much more. FCPX LUT Vintage Volume 2 is designed ...
(Date:6/25/2017)... ... June 25, 2017 , ... An increase in wetter weather in the ... and along with that; a humdinger of an allergy season. A relief from drought ... increase in misery-causing grass and weed pollen. , “Our patients have been reporting ...
(Date:6/25/2017)... ... ... Health Month and the focus is on prostate cancer. Second only to skin cancer, ... most common cause of cancer related death today; lung cancer remains in the number one ... cancer during his lifetime. Those at highest risk are men who have a ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman ... Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency ... the dentist fit into their patients’ busy lifestyles. Dental365 also gladly work with ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... the launch of Care Management Alerts and Dashboards, an innovative new service enabling ... Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data about ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology: